AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/article-1G1-199300614/hbl-portfolio-company-tolarex.html" title="Facts and information about HBL Portfolio Company Tolarex to Commence Phase I/IIa Trial of a Treatment for GVHD.">HBL Portfolio Company Tolarex to Commence Phase I/IIa Trial of a Treatment for GVHD.</a>

Close Set up an RSS feed that alerts you when new articles from Blood Weekly are available.

Frequently asked questions about RSS feeds

HBL Portfolio Company Tolarex to Commence Phase I/IIa Trial of a Treatment for GVHD.

Blood Weekly

| May 07, 2009 | COPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

Tolarex, a Hadasit Bio Holdings Ltd (HBL) portfolio company, announced that it has received approval by the Ministry of Health of Israel to begin a phase I/IIa clinical trial of its treatment for graft-versus-host disease (GVHD) (see also Hadasit Bio Holdings).

The first in man trial, anticipated to begin shortly, will evaluate the safety and preliminary possible efficacy of Tolarex's therapy. Twelve patients will be enrolled at two medical centers in Israel, Hadassah University Hospital in Ein Kerem included.

The therapies that exist today to treat GVHD are based on immunological suppression or the weakening of a patient's immune system, have low efficiency, can cause severe side effects and expose the…

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


Hadasit Bio-Holdings Ltd. Announced That Consensus Business Group, One of...: Press release article from: Business Wire May 29, 2007 700+ words
...in Shares. JERUSALEM -- Hadasit Bio-Holdings, Ltd. (HBL) a subsidiary...biotechnology, and especially in Hadasit Bio-Holdings. CBG is one of the prominent...and the rich potential of Hadasit Bio-Holdings, including products that...


Verto, a Subsidiary of Hadasit Bio-Holdings, Completes Successful Human...: Newspaper article from: Biotech Week August 6, 2008 700+ words
Hadasit Bio-Holdings, (HBL) a subsidiary of Hadasit...lupus erythematosus (see also Hadasit Bio-Holdings). The goals of the trial at...According to Ophir Shahaf, CEO of Hadasit Bio-Holdings, "We are proud of the results...


Hadasit Bio-Holdings HBL CEO Ophir Shahaf to Present at the 2009 Biotech...: Newspaper article from: Blood Weekly January 22, 2009 700+ words
Hadasit Bio-Holdings (TASE:HDST), announced that...at 10:15 a.m (see also Hadasit Bio-Holdings). The conference will take place...netvision.net.il. Keywords: Hadasit Bio-Holdings, Auto-immune Disease, Bioengineering...


KAHR Medical, a Hadasit Bio-Holdings Portfolio Company, Announces Scientific...: Newspaper article from: Blood Weekly March 5, 2009 700+ words
KAHR Medical, a Hadasit Bio-Holdings (HBL) (TASE: HDST) portfolio...Hodgkin's lymphoma (see also Hadasit Bio-Holdings). "TSCP molecules, with...Treatment, Tysabri, Zevalin, Hadasit Bio-Holdings. This article was prepared...


ProtAb, a Wholly Owned Subsidiary of Hadasit Bio Holdings, Receives U.S. Patent...: Press release article from: Business Wire December 2, 2008 700+ words
...ProtAb Ltd., a wholly owned subsidiary of Hadasit Bio-Holdings (TASE:HDST), announced today the receipt of...ProtAb is a portfolio company fully controlled by Hadasit Bio-Holdings Ltd. (HBL), which is listed on the Tel Aviv...


Hadasit Bio-Holdings (HBL) CEO Ophir Shahaf to Present at the 2009 Biotech...: Press release article from: Business Wire January 7, 2009 700+ words
...Nine Companies Are Based on Inventions Developed and Owned by Hadassah University Hospital EIN KEREM, Israel -- Hadasit Bio-Holdings (TASE:HDST), announced today that HBL CEO Mr. Ophir Shahaf will deliver a 15 minute presentation at the...


Hadasit Bio Holdings raises NIS 42m in convertible bonds.: Magazine article from: Israel Business Arena August 30, 2006 700+ words
(From Israel Business Arena) Hadasit Bio Holdings Ltd. (TASE:HDST), a subsidiary of Hadasit Ltd., the technology commercialization arm of Hadassah Medical Organization...


KAHR Medical Raises $500K From Hadasit Bio-Holdings and the Office of the Chief...: Press release article from: Business Wire January 28, 2009 700+ words
...Develop Two Products for the Treatment of Rheumatoid Arthritis and Psoriasis. JERUSALEM -- KAHR Medical, a Hadasit Bio-Holdings (HBL) (TASE:HDST) portfolio company, announced today that it has raised $500 thousand from HBL and the...


ProtAb, a wholly owned subsidiary of Hadasit Bio Holdings, receives US patent...: News wire article from: Chemical Business Newsbase December 2, 2008 700+ words
...thereof in the treatment of inflammatory and autoimmune diseases. ProtAb is a portfolio company fully controlled by Hadasit Bio-Holdings Ltd (HBL), which is listed on the Tel Aviv Stock Exchange.


Hadasit Bio to raise NIS 18m.: Magazine article from: Israel Business Arena March 23, 2009 700+ words
...Medical Organization subsidiary Hadasit Bio Holdings Ltd. (TASE:HDST) plans...institutional investors in the company. Hadasit Bio's share rose 1.1% on the...market cap of NIS 19 million. Hadasit Bio has already obtained commitments...

For more facts and information, see all results

Source: HighBeam Research, HBL Portfolio Company Tolarex to Commence Phase I/IIa Trial of a...

The AccessMyLibrary advertising network includes: